Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
31.2M
-
Shares change
-
-1.84M
-
Total reported value, excl. options
-
$43.4M
-
Value change
-
-$4.51M
-
Number of buys
-
32
-
Number of sells
-
-26
-
Price
-
$1.39
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q3 2020
68 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q3 2020.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.2M shares
.
Largest 10 shareholders include BROADWOOD CAPITAL INC (14.7M shares), PURA VIDA INVESTMENTS, LLC (6.02M shares), BlackRock Inc. (3.29M shares), VANGUARD GROUP INC (1.92M shares), STATE STREET CORP (685K shares), NORTHERN TRUST CORP (666K shares), GEODE CAPITAL MANAGEMENT, LLC (588K shares), Phoenix Holdings Ltd. (317K shares), Bank Julius Baer & Co. Ltd, Zurich (270K shares), and BRIDGEWAY CAPITAL MANAGEMENT INC (255K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.